Phylogica’s peptide vaccine program continues to produce encouraging in vivo data and has now been expanded beyond oncology to include viral illnesses that can be treated via the same vaccination strategy (T cell expansion and effector function)....
The peptide vaccine program continues to progress in the context of multiple different antigens (cargoes) and disease indications towards its ultimate read-out of complementarity to existing therapies in each of these indications to demonstrate improved treatment efficacy.
The goal is to demonstrate that PYC peptides can improve efficacy of existing therapies for certain viral indications that can be treated via T cell expansion and effector function?
HIV, Hep B and Hep C?
PYC Price at posting:
3.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)